Claims for Patent: 6,284,537

Summary for Patent: 6,284,537

Title:	Immortalized human corneal epithelial cell line
Abstract:	Immortalized human cornea). epithelial cell line capable of becoming stratified, and capable of expressing (1) metabolic markers specific for non-immortalized human epithelial cells such as vimentin, cytokeratins, connections between the cells, cytochrome P450s, a glutathione-S-transferase, Cu/Zn-superoxide dismutase, glutathione peroxidase, aldehyde reductase and catalase; (2) metabolic differentiation markers specific for non-immortalized human cornea). epithelial cells such as the cytokeratin of 64 kfl, the glutathione-stransferase hGST 5.8, and the profile of cytokines and growth factors comprising the compounds TNF.alpha., IL-1.beta., IL-1.alpha., IL-6, IL-8, GM CSF-.beta., IL-ra, TGF-.beta.1, TGF-.beta.2, TGF.alpha., EGF, PDGF-.beta.; (3) and markers specific for an inflammatory reaction such as collagenase I, the bradykinin, histamine and PAF receptors, and the system for transduction of an inflammatory signal by the phosphoinositides. Process for identifying the mutagenic, toxic or beneficial effect of an agent on the metabolism of the corneal cells, in which (1) an agent suspected of being a mutagenic, toxic or beneficial agent for the metabolism of the cells of the human cornea is reacted, cultured or brought into contact with a culture comprising a cell line according to the invention, and (2) the effects of the said agent on the said cell line are determined or measured.
Inventor(s):	Offord Cavin; Elizabeth (Poliez-Pittet, CH), Pfeifer; Andrea M. A. (St-Legier, CH), Sharif; Najam A. (Arlington, TX), Tromvoukis; Yvonne (Mollie-Margot, CH)
Assignee:	Nestec S.A. (Vevey, CH)
Application Number:	08/997,588
Patent Claims:	1. An immortalized cell line which has the deposit number CNCM I-1777. 2. A method for determining mutagenic, toxic or beneficial effects of an agent on metabolism of cornea cells, which comprises: reacting, culturing or contacting a culture comprising the cell line of claim 1 with the agent; and determining or measuring the mutagenic, toxic or beneficial effects of the agent on the cell line. 3. A diagnostic kit for identifying a mutagenic, toxic, or beneficial agent on the metabolism of cornea cells comprising: (a) a cell line which has the deposit number CNCM I-1777; and (b) reagents for determining a metabolic response of the cell line to mutagenic, toxic or beneficial agents. 4. The diagnostic kit of claim 3, wherein the reagents comprise a nucleic acid or an antibody. 5. The diagnostic kit of claim 3, wherein the reagents detect collagenase I.

Details for Patent 6,284,537

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2016-12-24